XMT 1001

11/12/2009 - "XMT-1001 is being evaluated in patients with advanced cancer in an ongoing Phase 1 trial."
05/01/2012 - "XMT-1001 provides an extended systemic and tumor exposure of conjugated drug and shows improved antitumor effect compared with CPT-11."
05/01/2012 - "XMT-1001 was administered intravenously to female athymic nude (nu/nu) mice bearing established HT-29 xenograft tumors (n = 10) at 15, 30, and 60 mg CPT equivalents/kg on weekly or biweekly schedules. "
11/12/2009 - "XMT-1001 has an improved therapeutic window compared to CPT and irinotecan in human tumor xenograft models, providing a compelling rationale for clinical development. "
11/12/2009 - "XMT-1001, a novel polymeric camptothecin pro-drug in clinical development for patients with advanced cancer."

05/01/2012 - "The antitumor efficacy of XMT-1001 was evaluated in the mouse HT-29 human colon carcinoma xenograft model. "
05/01/2012 - "Pharmacokinetics and antitumor efficacy of XMT-1001, a novel, polymeric topoisomerase I inhibitor, in mice bearing HT-29 human colon carcinoma xenografts."